IDENTIFICATION OF A GRAFT-VERSUS-HOST DISEASE-ASSOCIATED HUMAN MINOR HISTOCOMPATIBILITY ANTIGEN
IDENTIFICATION OF A GRAFT-VERSUS-HOST DISEASE-ASSOCIATED HUMAN MINOR HISTOCOMPATIBILITY ANTIGEN
复制标题
DOI：
10.1126/science.7539551
复制
发表时间：
1995-06-09
期刊：
影响因子：
56.9
通讯作者：
GOULMY, E
中科院分区：
文献类型：
--
作者：
DENHAAN, JMM;SHERMAN, NE;GOULMY, E
人类白细胞抗原（HLA）匹配的骨髓供体和受体之间微小的组织相容性抗原差异是移植物抗宿主病（GVHD）的主要危险因素。一个hla - a2.1限制的细胞毒性T细胞克隆识别次要组织相容性抗原HA-2，此前从一个hla相同的骨髓移植后的严重GVHD患者中分离出来。现在已经确定了代表HA-2的hla - a2.1结合肽。这种肽似乎起源于非丝形成类I肌球蛋白家族的成员。由于HA-2在hla - a2.1阳性人群中具有95%的表型频率，因此它是骨髓移植免疫治疗干预的候选基因。
Minor histocompatibility antigen disparities between human leukocyte antigen (HLA)-matched bone marrow donors and recipients are a major risk factor for graft versus host disease (GVHD). An HLA-A2.1-restricted cytotoxic T cell clone that recognized the minor histocompatibility antigen HA-2 was previously isolated from a patient with severe GVHD after HLA-identical bone marrow transplantation. The HLA-A2.1-bound peptide representing HA-2 has now been identified. This peptide appears to originate from a member of the non-filament-forming class I myosin family. Because HA-2 has a phenotype frequency of 95 percent in the HLA-A2.1-positive population, it is a candidate for immunotherapeutic intervention in bone marrow transplantation.